Literature DB >> 33252078

Plasma Biomarkers of Alzheimer's Disease in African Americans.

Kaancan Deniz1, Charlotte C G Ho1, Kimberly G Malphrus1, Joseph S Reddy2, Thuy Nguyen1, Troy P Carnwath1, Julia E Crook2, John A Lucas3, Neill R Graff-Radford4, Minerva M Carrasquillo1, Nilüfer Ertekin-Taner1,4.   

Abstract

BACKGROUND/
OBJECTIVE: The aim of this study was to determine if plasma concentrations of 5 surrogate markers of Alzheimer's disease (AD) pathology and neuroinflammation are associated with disease status in African Americans.
METHODS: We evaluated 321 African Americans (159 AD, 162 controls) from the Florida Consortium for African-American Alzheimer's Disease Studies (FCA3DS). Five plasma proteins reflecting AD neuropathology or inflammation (Aβ42, tau, IL6, IL10, TNFα) were tested for associations with AD, age, sex, APOE and MAPT genotypes, and for pairwise correlations.
RESULTS: Plasma tau levels were higher in AD when adjusted for biological and technical covariates. APOEɛ4 was associated with lower plasma Aβ42 and tau levels. Older age was associated with higher plasma Aβ42, tau, and TNFα. Females had lower IL10 levels. Inflammatory proteins had strong pairwise correlations amongst themselves and with Aβ42.
CONCLUSION: We identified effects of demographic and genetic variants on five potential plasma biomarkers in African Americans. Plasma inflammatory biomarkers and Aβ42 may reflect correlated pathologies and elevated plasma tau may be a biomarker of AD in this population.

Entities:  

Keywords:  African Americans; Alzheimer’s disease; biomarkers; minority health

Year:  2021        PMID: 33252078      PMCID: PMC7902984          DOI: 10.3233/JAD-200828

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  46 in total

Review 1.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Authors:  Richard Mayeux; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.

Authors:  Erdinç Dursun; Duygu Gezen-Ak; Haşmet Hanağası; Başar Bilgiç; Ebba Lohmann; Sibel Ertan; İrem L Atasoy; Merve Alaylıoğlu; Ömür Selin Araz; Burak Önal; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Turgut Ulutin; Hakan Gürvit; Selma Yılmazer
Journal:  J Neuroimmunol       Date:  2015-04-25       Impact factor: 3.478

3.  Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies.

Authors:  Xue-Ning Shen; Li-Dong Niu; Yan-Jiang Wang; Xi-Peng Cao; Qiang Liu; Lan Tan; Can Zhang; Jin-Tai Yu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-01-10       Impact factor: 10.154

4.  Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease.

Authors:  Ching-Wen Huang; Shang-Jang Wang; Shyh-Jong Wu; Ching-Chung Yang; Ming-Wei Huang; Chieh-Hsin Lin; Irene H Cheng
Journal:  Am J Alzheimers Dis Other Demen       Date:  2012-12-10       Impact factor: 2.035

Review 5.  Immune attack: the role of inflammation in Alzheimer disease.

Authors:  Frank L Heppner; Richard M Ransohoff; Burkhard Becher
Journal:  Nat Rev Neurosci       Date:  2015-06       Impact factor: 34.870

Review 6.  Alzheimer's disease in African Americans: risk factors and challenges for the future.

Authors:  Lisa L Barnes; David A Bennett
Journal:  Health Aff (Millwood)       Date:  2014-04       Impact factor: 6.301

7.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Authors:  Neill R Graff-Radford; Julia E Crook; John Lucas; Bradley F Boeve; David S Knopman; Robert J Ivnik; Glenn E Smith; Linda H Younkin; Ronald C Petersen; Steven G Younkin
Journal:  Arch Neurol       Date:  2007-03

Review 8.  Genetics of Alzheimer's disease: a centennial review.

Authors:  Nilüfer Ertekin-Taner
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

9.  Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.

Authors:  Mariet Allen; Michaela Kachadoorian; Zachary Quicksall; Fanggeng Zou; High Seng Chai; Curtis Younkin; Julia E Crook; V Shane Pankratz; Minerva M Carrasquillo; Siddharth Krishnan; Thuy Nguyen; Li Ma; Kimberly Malphrus; Sarah Lincoln; Gina Bisceglio; Christopher P Kolbert; Jin Jen; Shubhabrata Mukherjee; John K Kauwe; Paul K Crane; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Joseph E Parisi; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  Alzheimers Res Ther       Date:  2014-07-01       Impact factor: 6.982

10.  Aging and APOE-ε4 are determinative factors of plasma Aβ42 levels.

Authors:  Takumi Nakamura; Takeshi Kawarabayashi; Yusuke Seino; Mie Hirohata; Naoko Nakahata; Sakiko Narita; Ken Itoh; Shigeyuki Nakaji; Mikio Shoji
Journal:  Ann Clin Transl Neurol       Date:  2018-09-07       Impact factor: 4.511

View more
  4 in total

1.  Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Xulong Ding; Shuting Zhang; Lijun Jiang; Lu Wang; Tao Li; Peng Lei
Journal:  Transl Neurodegener       Date:  2021-03-12       Impact factor: 8.014

2.  Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels.

Authors:  Chloé Sarnowski; Mohsen Ghanbari; Joshua C Bis; Mark Logue; Myriam Fornage; Aniket Mishra; Shahzad Ahmad; Alexa S Beiser; Eric Boerwinkle; Vincent Bouteloup; Vincent Chouraki; L Adrienne Cupples; Vincent Damotte; Charles S DeCarli; Anita L DeStefano; Luc Djoussé; Alison E Fohner; Carol E Franz; Tiffany F Kautz; Jean-Charles Lambert; Michael J Lyons; Thomas H Mosley; Kenneth J Mukamal; Matthew P Pase; Eliana C Portilla Fernandez; Robert A Rissman; Claudia L Satizabal; Ramachandran S Vasan; Amber Yaqub; Stephanie Debette; Carole Dufouil; Lenore J Launer; William S Kremen; William T Longstreth; M Arfan Ikram; Sudha Seshadri
Journal:  Commun Biol       Date:  2022-04-08

3.  Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans.

Authors:  Joseph S Reddy; Jiangli Jin; Sarah J Lincoln; Charlotte C G Ho; Julia E Crook; Xue Wang; Kimberly G Malphrus; Thuy Nguyen; Nikoleta Tamvaka; Maria T Greig-Custo; John A Lucas; Neill R Graff-Radford; Nilüfer Ertekin-Taner; Minerva M Carrasquillo
Journal:  EBioMedicine       Date:  2022-03-17       Impact factor: 11.205

4.  Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort.

Authors:  James R Hall; Melissa Petersen; Leigh Johnson; Sid E O'Bryant
Journal:  Front Neurol       Date:  2022-08-18       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.